Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2023-10-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's fifth board of directors' third meeting held on October 30, 2023. It includes voting results on various proposals such as approval of the 2023 third quarter report, adjustments to the company's equity structure, and revisions to internal governance rules. The document is not the report itself but an announcement of board meeting decisions and resolutions. It does not contain detailed financial statements or comprehensive report content. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2023-10-30 Chinese
关于控股股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a controlling shareholder. It details the number of shares released from pledge, the shareholder's total pledged shares, and related information. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Major Shareholding Notification (MRQ) as it involves significant shareholding changes and disclosures related to share pledges by major shareholders.
2023-10-23 Chinese
关于获得创新药HSK21542注射液上市许可《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving an acceptance notice ('受理通知书') from the National Medical Products Administration for the marketing authorization application of an innovative drug. It describes the drug, its clinical research, and the significance of the acceptance. The document is short (1245 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory milestone rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-18 Chinese
关于获得创新药HSK39297片IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration for an IND (Investigational New Drug) application for a new drug. It describes the drug development project and includes a risk warning for investors. The document is short (836 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval event related to drug development, not a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-10-12 Chinese
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, and related information about the shareholder's stock pledge. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledging activity, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Capital/Financing Update or Major Shareholding Notification, since it is about share pledge rather than ownership change or capital raising.
2023-10-10 Chinese
关于收购控股子公司股权的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of an acquisition of controlling subsidiary shares by the company. It details the approval of the acquisition, signing of the share transfer agreement, payment completion, and share transfer completion. It does not contain full financial statements or detailed financial performance data. It is a corporate announcement about a capital transaction related to subsidiary shareholding. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2023-10-09 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.